Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban PK in Nephrotic Syndrome
NCT02599532Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Apr 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of apixaban in venous thromboembolism (VTE) (2 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Area under the concentration versus time curve. Started Apr 2017; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02599532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599532.